Cargando…

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics

The purpose of this study was to identify clinician characteristics associated with higher prescription rates of long-acting injectable (LAI) antipsychotics, as well as the sources that influence medical decision-making regarding the treatment of schizophrenia. We surveyed 202 psychiatrists during s...

Descripción completa

Detalles Bibliográficos
Autores principales: Samalin, Ludovic, Garnier, Marion, Auclair, Candy, Llorca, Pierre-Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133930/
https://www.ncbi.nlm.nih.gov/pubmed/27869767
http://dx.doi.org/10.3390/ijms17111935
_version_ 1782471370934845440
author Samalin, Ludovic
Garnier, Marion
Auclair, Candy
Llorca, Pierre-Michel
author_facet Samalin, Ludovic
Garnier, Marion
Auclair, Candy
Llorca, Pierre-Michel
author_sort Samalin, Ludovic
collection PubMed
description The purpose of this study was to identify clinician characteristics associated with higher prescription rates of long-acting injectable (LAI) antipsychotics, as well as the sources that influence medical decision-making regarding the treatment of schizophrenia. We surveyed 202 psychiatrists during six regional French conferences (Bordeaux, Lyon, Marseille, Nice, Paris, and Strasbourg). Data on the characteristics of practice, prescription rates of antipsychotic, and information sources about their clinical decisions were collected. Most psychiatrists used second-generation antipsychotics (SGAs), and preferentially an oral formulation, in the treatment of schizophrenia. LAI SGAs were prescribed to 30.4% of schizophrenic patients. The duration and type of practice did not influence the class or formulation of antipsychotics used. The clinicians following the higher percentage of schizophrenic patients were associated with a higher use of LAI antipsychotics and a lower use of oral SGAs. Personal experience, government regulatory approval, and guidelines for the treatment of schizophrenia were the three main contributing factors guiding clinicians’ decision-making regarding the treatment of schizophrenia. The more clinicians follow schizophrenic patients, the more they use LAI antipsychotics. The development of specialized programs with top specialists should lead to better use of LAI antipsychotics in the treatment of schizophrenia.
format Online
Article
Text
id pubmed-5133930
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-51339302016-12-12 Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics Samalin, Ludovic Garnier, Marion Auclair, Candy Llorca, Pierre-Michel Int J Mol Sci Article The purpose of this study was to identify clinician characteristics associated with higher prescription rates of long-acting injectable (LAI) antipsychotics, as well as the sources that influence medical decision-making regarding the treatment of schizophrenia. We surveyed 202 psychiatrists during six regional French conferences (Bordeaux, Lyon, Marseille, Nice, Paris, and Strasbourg). Data on the characteristics of practice, prescription rates of antipsychotic, and information sources about their clinical decisions were collected. Most psychiatrists used second-generation antipsychotics (SGAs), and preferentially an oral formulation, in the treatment of schizophrenia. LAI SGAs were prescribed to 30.4% of schizophrenic patients. The duration and type of practice did not influence the class or formulation of antipsychotics used. The clinicians following the higher percentage of schizophrenic patients were associated with a higher use of LAI antipsychotics and a lower use of oral SGAs. Personal experience, government regulatory approval, and guidelines for the treatment of schizophrenia were the three main contributing factors guiding clinicians’ decision-making regarding the treatment of schizophrenia. The more clinicians follow schizophrenic patients, the more they use LAI antipsychotics. The development of specialized programs with top specialists should lead to better use of LAI antipsychotics in the treatment of schizophrenia. MDPI 2016-11-19 /pmc/articles/PMC5133930/ /pubmed/27869767 http://dx.doi.org/10.3390/ijms17111935 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Samalin, Ludovic
Garnier, Marion
Auclair, Candy
Llorca, Pierre-Michel
Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
title Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
title_full Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
title_fullStr Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
title_full_unstemmed Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
title_short Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
title_sort clinical decision-making in the treatment of schizophrenia: focus on long-acting injectable antipsychotics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133930/
https://www.ncbi.nlm.nih.gov/pubmed/27869767
http://dx.doi.org/10.3390/ijms17111935
work_keys_str_mv AT samalinludovic clinicaldecisionmakinginthetreatmentofschizophreniafocusonlongactinginjectableantipsychotics
AT garniermarion clinicaldecisionmakinginthetreatmentofschizophreniafocusonlongactinginjectableantipsychotics
AT auclaircandy clinicaldecisionmakinginthetreatmentofschizophreniafocusonlongactinginjectableantipsychotics
AT llorcapierremichel clinicaldecisionmakinginthetreatmentofschizophreniafocusonlongactinginjectableantipsychotics